Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Bridge BioResearch Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Bridge BioResearch Ltd.
ClinicalTrials.gov Identifier:
NCT01342497
First received: April 12, 2011
Last updated: December 22, 2011
Last verified: December 2011

April 12, 2011
December 22, 2011
July 2011
August 2012   (final data collection date for primary outcome measure)
Rate of healing of diabetic foot ulcers (% reduction in area from baseline) [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
Rate of healing of diabetic foot ulcers (% reduction in area) [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01342497 on ClinicalTrials.gov Archive Site
  • Rate of healing (change from baseline) as assessed by various scoring criteria: IDSA, modified ASEPSIS score, TEXAS Diabetic wound score, composite severity score and global clinical assessment [ Time Frame: week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up) ] [ Designated as safety issue: No ]
  • Effect of BBR-012 on the level of ischemia (change from baseline as measured by tcpO2) [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
  • Effect of BBR-012 on microbiological outcome (presence of pathogens and outcome as compared to baseline) [ Time Frame: week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up) ] [ Designated as safety issue: No ]
  • Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters [ Time Frame: from baseline visit to week 14 ] [ Designated as safety issue: Yes ]
  • Rate of healing as assessed by various scoring criteria: IDSA, modified ASEPSIS score, TEXAS Diabetic wound score, composite severity score and global clinical assessment [ Time Frame: week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up) ] [ Designated as safety issue: No ]
  • Effect of BBR-012 on the level of ischemia (as measured by tcpO2) [ Time Frame: 4, 8 and 12 weeks ] [ Designated as safety issue: No ]
  • Effect of BBR-012 on microbiological outcome (presence of pathogens and outcome) [ Time Frame: week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up) ] [ Designated as safety issue: No ]
  • Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters [ Time Frame: from baseline visit to week 14 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study
A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)

The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetic Foot Ulcer
  • Drug: isoniazide
    Tablets, dosing 3 times daily, 12 weeks
  • Drug: placebo
    tablets, dosing 3 times daily, 12 weeks
  • Experimental: BBR-012
    Intervention: Drug: isoniazide
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
August 2012
August 2012   (final data collection date for primary outcome measure)

Main Inclusion Criteria:

  • Aged ≥18
  • Diabetes mellitus
  • Ischaemic or neuro-ischaemic Diabetic Foot Ulcer below the malleolus, but not wholly on the sole of the foot (minimum size: 1 cm x 1 cm)
  • Body Mass Index(BMI) ≤40 kg/m2
  • Women of childbearing potential must use acceptable methods of birth control
  • Written informed consent to participate in the study
  • Patients must be able to speak English fluently and to understand English

Main Exclusion Criteria:

  • Any uncontrolled illnesses (e.g. active malignancy, vasculitis) that, in the opinion of the investigator, would interfere with interpreting the results of the study
  • Infected Diabetic Foot Ulcer based on the IDSA guidelines, i.e. presence of purulent secretions or at least two of the manifestations of inflammation (erythema, warmth, swelling or induration and pain or tenderness), and for whom, in the investigator's judgment, intravenous or oral antibiotic therapy is required
  • Active osteomyelitis
  • Wholly plantar Diabetic Foot Ulcer
  • Suspected gangrenous tissue of the affected limb that cannot be removed with a single debridement
  • Diabetic Foot Ulcer associated with prosthetic material or a device
  • Received any potentially effective systemic antibiotic therapy for more than 24 hours during the 72-hour period before the screening visit
  • Is receiving, or has received within the 14 days prior to the screening visit, any concomitant topical wound therapy (e.g., topical antimicrobial therapy, topical debriding agent, topical growth factor, topical skin replacement, or hyperbaric oxygen)
  • Has received systemic corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy within the 30 days prior to the screening visit.
  • Hepatic impairment, renal impairment (defined as estimated glomerular filtration rate <10 mL/minute/1.73m2), hypersensitivity to isoniazid.
  • High risk for tuberculosis, e.g. HIV positive, are immunosuppressed, or have active malignancy
  • Symptoms of active or latent tuberculosis (based on specific history, physical examination, Interferon Gamma Release Assay (IGRA) test and chest X-Ray)
  • Known or suspected drug or alcohol abuse or positive drugs of abuse test.
  • Participating in any clinical study the 12 weeks before the screening visit
  • Donation of more than 450 mL of blood in the 3 months before the screening visit, or 1200 mL blood in the 12 months before the screening visit.
  • History of severe hypersensitivity or ongoing hypersensitivity that might affect the patient's suitability for the study (e.g. hypersensitivity to wound dressings), as judged by the investigator.
  • History of allergy to, or insensitivity to, local anaesthetics
  • Use of any prescribed or non-prescribed (over-the-counter) medication, including herbal medication (e.g., St. Johns Wort) that could possibly interfere with the objectives of this study (e.g., could affect the closure of chronic dermal ulceration), during 2 weeks (or 5 half-lives of the compound whichever is the longer) before the anticipated first dose of study medication. Occasional paracetamol for pain relief (maximum 2 g per 24 hours) and adrenergic nasal spray for relief of nasal congestion are allowed
  • Having received BBR-012 or isoniazid within the 6 months prior to the screening visit
  • Bleeding disorder or history of increased bleeding
Both
18 Years and older
No
Contact: Andrew Boulton, Professor 0161 276 4406 aboulton@med.miami.edu
United Kingdom
 
NCT01342497
BBR-012CS01
Yes
Bridge BioResearch Ltd.
Bridge BioResearch Ltd.
Not Provided
Principal Investigator: Andrew J Boulton, Professor Manchester Royal Infirmary
Bridge BioResearch Ltd.
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP